Latest News and Press Releases

ZyVersa engages CRO, George Clinical, to manage its P2a clinical trial with VAR 200 in Diabetic Kidney Disease expected to begin Q1-2024.

Plasma NLRP3 inflammasomes are significantly elevated in early-stage diabetic kidney disease, and levels progressively increase as kidney function worsens.

WESTON, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or “the Company”), a clinical stage specialty biopharmaceutical company developing...

AIM2 and NLRP3 inflammasome activation leads to development of atherosclerotic lesions in diabetic mice.

WESTON, Fla., Nov. 30, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or the “Company”), a clinical stage specialty biopharmaceutical company developing...

Key Corporate Highlights: Progressing toward Q1-2024 initiation of a proof-of-concept clinical trial with Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease...

NLRP3 inflammasome inhibition attenuates intestinal inflammation and tissue damage, and significantly improves symptoms in IBD animal model.

Air pollution linked with development and progression of chronic kidney disease that can be attenuated by inhibiting inflammasome NLRP3 activation.

NLRP3 Inflammasome Inhibition Alleviates Neurological Impairment in the Brain of MS Mouse Model, Reinforcing Published Data for IC 100 in MS Mouse Model.

Obesity exacerbates scarring of the heart through ASC-driven inflammasome activation in the heart leading to damaging inflammation.